Christian’s research education and continued research interest stems from translational lab work within cancer immunology. This led to his establishing research facilities and networks within this area. He has been involved in more than 50 clinical trials and has headed research, including clinical trial units focusing on translational clinical trials, at Sørlandet Hospital and Akershus University Hospital.

He has always been intrigued by the Biotech industry and has experience from Big Pharma (Roche).

Marte's clinical practice and research interests converge upon symptom management, where pain is central. She built her PhD project from the ground up, creating a national network of radiation oncologists which expanded her pilot to a multicenter study investigating the effects of palliative radiotherapy of prostate and rectal cancers throughout Norway.

Since 2020, she has been Medical Head of Research at the Center for Cancer Treatment at Sørlandet Hospital.

Stig works primarily with commercialization of R&D and growth companies in various parts of the technology segment (incl. SW, SW/HW, Deep Tech, Health Tech and Biotech/Life Science).

He assists startups and mature companies at various stages of their development, and continuously works with technology investors, business angel funds and venture funds, as well as their portfolio-companies. Stig holds formal competence from the MIT Sloan School of Management and NTNU (Institute for Industrial Economics), and practical experience related to entrepreneurship, business modelling, innovation and strategy.

Gry holds a PhD in pharmaceutical technology and a Master of management. She has served in leading positions within Chemistry, Manufacturing, and Controls (CMC) development in several Biotech companies and has in these role passionately contributed beyond the tasks of CMC, including regulatory and management functions.

Paula Bousquet is a meticulous scientist with experience within drug development, both as a scientist and on the leadership level from both industry and public sector. Most importantly, she has extensive methodological experience from public and private drug development initiatives targeting the EGFR.

Soheil is the Chief Operating Officer at AKIGAI harnessing over a decade of operative experience, he is responsible for creating AKIGAI’s operational excellence. Previously, as Co-Founder and former CEO of Diffia, he played a pivotal role in the development of Nimble, a mobile-first clinical ICT system designed to enhance patient care.

Morten has a strong track record in company financing, structural change and planning processes. He has a particular emphasis on financing research, development and innovation projects. In addition, he has hands-on experience in facilitating, structuring and leading the implementation of joint industry projects (JIPs).
He has served as CFO and/or COO and has board experience from several venture-backed companies.

Gerard is a trained physician with 40 years of Business Development experience from major pharmaceutical companies such as Daiichi Sankyo, Grünenthal, Teva, etc. He has contributed to over 100 licensing agreements and has extensive expertise in the marketing of repurposed products. He contributes to AKIGAI's development as a Business Development advisor and Board member.

Kjetil has extensive experience in entrepreneurship and leading companies in Biopharma/Medtech with a demonstrated executive history of pre-clinical and clinical product development and commercialization both through partnership and own commercialization. He serves as a CEO for Serca Pharmaceuticals and Caedo Oncology, in addition to the board of AKIGAI and Lytix Biopharma.

Jutta holds a PhD in molecular biology and has board education from INSEAD in Paris and is now a Board member in AKIGAI. She has for many years been Head of International Affairs for Oslo Cancer Cluster and has built up a strong network within the Pharma and Biotech-VC community. Her network includes a broad range of stakeholders including academic investigators, clinicians, technology transfer offices, start-ups, biotech and international Pharma companies, investors, clusters and innovation hubs.

Morten has a background as a pilot in the Norwegian military which has helped him to develop the ability to quickly identify critical question sin complex contexts. He has also worked as a mentor, has established his own company supplying clothing and equipment for Nordic defense and police. Morten is also a board member of the Norwegian medtech company InVivo Bionics. Morten is an investor and Board member in AKIGAI.

Aslak is an extraordinary IT-savvy, diligent and experienced research nurse. He is safeguarding the GCP compliant conduct of the AKIGAI studies.

‍